Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBRT with or without 177Lu-PSMA for recurrent prostate cancer after prostatectomy
ACTRN12618001667202Phase 3Not yet recruiting
- Sponsor
- GenesisCare
- Start
- Nov 2018
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa) (2 arms), sponsored by GenesisCare. Primary endpoint: PSA response rate. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ACTRN12618001667202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001667202.